WAVE Life Sciences
733 Concord Avenue
About WAVE Life Sciences
WAVE Life Sciences is a preclinical genetic medicine company focused on advancing first-in-class or best-in-class stereopure nucleic acid therapies for patients impacted by rare diseases. We are utilizing our innovative and proprietary synthetic chemistry platform to design and develop nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, with a goal of delivering new and exceptional treatment options for patients. Given the versatility of our chemistry, WAVE’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi, potentially enabling us to address a broad range of therapeutic areas and diseases.
CEO: Paul Bolno
CFO: Keith Regnante
Please click here for Wave Life Sciences.
Please click here for clinical trial information.
FOLLOW WAVE LIFE SCIENCES:
Tweets by Wave Life Sciences
39 articles with WAVE Life Sciences
Wave Life Sciences Announces Positive Phase 1 Results for WVE-210201 in Duchenne Muscular Dystrophy (DMD)
Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that the safety and tolerability data from the WVE-210201 Phase 1 clinical trial in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping support initiation of a Phase 2/3 clinical trial.
Research will focus on inherited retinal diseases associated with RHO, USH2A, ABCA4 and CEP290
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it has entered into a research, development and commercial collaboration and multi-program option agreement with Wave Life Sciences Ltd.
Preclinical Data Supporting Wave Life Sciences ALS and FTD Programs Presented at 28th International Symposium on ALS/MND
Lead candidate targets C9ORF72; in vivo animal data demonstrate potent, sustained and preferential knockdown of toxic biomarkers associated with ALS and FTD.
Wave reported a net loss of $26.1 million for the third quarter of 2017, as compared to a net loss of $17.5 million for the third quarter of 2016.
This clinical trial marks the next stage in the company’s ongoing commitment to address the significant unmet needs of patients diagnosed with this devastating disease and it is the company’s third clinical trial initiated in 2017.
10/27/2017Wave Life Sciences has officially opened a new state-of-the art manufacturing facility to support advancement of the company’s stereopure nucleic acid platform.
WAVE Life Sciences Announces Publication Of Paper In Nature Biotechnology Establishing The Importance Of Stereochemical Purity In Oligonucleotide Drug Design
WAVE Life Sciences Initiates Two Phase 1b/2a Clinical Trials: PRECISION-HD1 And PRECISION-HD2 In Patients With Huntington’s Disease
WAVE Life Sciences Reports Fourth Quarter And Full-Year 2016 Financial Results And Provides Business Update
nLife Therapeutics Enters Research Collaboration With WAVE Life Sciences To Explore Targeting Of Nucleic Acids To Specific Cell-Types In The Central Nervous System